3
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T37460 |
Lipoxin B4
Lipoxin B4 |
||
Lipoxin B4 (LXB4) is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15(S)-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM. | |||
T38308 |
Lipoxin B4 methyl ester
|
||
Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4 . LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM. | |||
T36052 |
Lipoxin A4 methyl ester
LXA4 methyl ester |
||
Lipoxin A4 methyl ester (LXA4 methyl ester) is a more lipid soluble, prodrug formulation of the transcellular metabolite LXA4. LXA4 is a trihydroxy fatty acid containing a conjugated tetraene, produced by the metabolism of 15-HETE or 15-HpETE with human leukocytes.[1] LXA4 is equipotent to leukotriene B4 (LTB4) in inducing superoxide generation in human neutrophils at 0.1 μM.[2] LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis effects, natural... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36051 |
Lipoxin A4
脂氧素 A4,LXA4 |
||
Lipoxin A4 (LXA4) is a trihydroxy fatty acid containing a conjugated tetraene, produced by the metabolism of (±)15-HETE or 15-HpETE with human leukocytes.[1] LXA4 is equipotent to leukotriene B4 in inducing superoxide generation in human neutrophils at 0.1 μM.2 LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis effects, natural killer cell inhibition, and monocyte migration and adhesion.[2],[3],[4] Analytical and biological comparisons of synth... |